ASCL3

Across TCGA pan-cancer cohorts, ASCL3 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated ASCL3 data layer compared with 2 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ASCL3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ASCL3 expression acts as an unfavorable survival marker, although some lineages such as SCLC and ESCA show a favorable association.

LIHC, ACC, and HNSC are the cancer types where ASCL3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.377	0.575	<.001	100	view →
ACC	OS	Tertile	All	0.229	0.681	<.001	81	view →
HNSC	DFS	Tertile	III,IV	0.279	0.579	<.001	47	view →
SCLC	DFS	Median	II,III,IV	0.833	0.190	<.001	43	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
SKCM	DFS	Tertile	II,III,IV	0.575	0.749	.014	33	view →
UVM	OS	Tertile	III,IV	0.037	0.809	<.001	24	view →
COAD	OS	Tertile	All	0.310	0.602	.013	21	view →
MESO	OS	Quartile	IV	0.077	0.656	.001	12	view →
KIRC	DFS	Quartile	IV	0.220	0.469	.036	8	view →
ESCA	DFS	Quartile	III,IV	0.660	0.346	.020	3	view →
CHOL	DFS	Median	II,III,IV	0.708	0.220	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

ASCL3–LIHC (DFS)

Open the LIHC breakdown →